Unlocking the Potential of Non-Viral Genetic Medicine: A New Approach to Treating Bladder Cancer
A preliminary trial indicates potential progress in treating non-muscle invasive bladder cancer (NMIBC). enGene, a biopharmaceutical company, is advancing its Phase 2 LEGEND trial to evaluate detalimogene voraplasmid, a non-viral genetic medicine, for NMIBC. In the United States, bladder cancer is linked to over 17,000 deaths as of 2025, with approximately 85,000 diagnoses annually, 75-85% […]










